RayKnowChina Research Map
Shortlist

Lanzhou

Lanzhou University Second Hospital

兰州大学第二医院

Listed for 27 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Lanzhou University Second Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Oesophageal squamous cell carcinoma食管鳞状细胞癌10 papers led
  2. Hepatocellular carcinoma肝细胞癌45 papers led
  3. Stomach cancer胃癌108 papers led
  4. Lung cancer肺癌41 papers led
  5. Pancreatic cancer胰腺癌46 papers led
  6. Breast cancer乳腺癌17 papers led1 open trial led
  7. Glioma胶质瘤52 papers led
  8. Chordoma脊索瘤1 paper led
  9. Osteosarcoma骨肉瘤15 papers led
  10. Gastrointestinal stromal tumour胃肠道间质瘤5 papers led
  11. Neuroblastoma神经母细胞瘤2 papers led
  12. Ewing sarcoma尤文肉瘤2 papers led
  13. Multiple myeloma多发性骨髓瘤12 papers led
  14. Lymphoma淋巴瘤16 papers led
  15. IgG4-related diseaseIgG4相关性疾病2 papers led
  16. Myasthenia gravis重症肌无力2 papers led
  17. Coronary heart disease冠心病13 papers led
  18. Congenital heart disease先天性心脏病4 papers led
  19. Scoliosis脊柱侧弯9 papers led
  20. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  21. Takayasu arteritis大动脉炎0 papers led
  22. Idiopathic pulmonary fibrosis特发性肺纤维化0 papers led
  23. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  24. IgA nephropathyIgA 肾病2 papers led
  25. Gaucher disease戈谢病0 papers led
  26. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  27. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led

Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Moyamoya disease, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Behçet disease, Alport syndrome, Niemann–Pick disease type C, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 10 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 2220232024: 1120242025: 222025

3 hospitals in Lanzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentMolecular markers & genomicsImaging & AI
Departments in papersMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led10
  1. Predictive value of 18F-FDG PET/CT-based radiomics model for lymph node metastasis in esophageal squamous cell carcinoma.2026Annals of nuclear medicine
  2. BRD4 Induces Esophageal Squamous Cell Carcinoma Progression via the Wnt/β-catenin Pathway.2026Biochemical geneticsFree full text
  3. Neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study with 2-year survival analysis.2025Journal of cancer research and clinical oncologyFree full text
  4. PYCR1 Promotes Esophageal Squamous Cell Carcinoma by Interacting With EGFR to Affecting the PI3K/Akt/mTOR Signaling Pathway.2025The journal of gene medicine
  5. Downregulation of ALDH5A1 suppresses cisplatin resistance in esophageal squamous cell carcinoma by regulating ferroptosis signaling pathways.2024Molecular carcinogenesis
  6. Utility of near-infrared fluorescence imaging with indocyanine green in resection of oesophageal squamous cell carcinoma: A literature review and a case report.2023Photodiagnosis and photodynamic therapy
  7. Molecular mechanism underlying epithelial-mesenchymal transformation and cisplatin resistance in esophageal squamous cell carcinoma.2023Thoracic cancerFree full text
  8. Epithelial-Mesenchymal Transition Gene Signature Is Associated with Neoadjuvant Chemoradiotherapy Resistance and Prognosis of Esophageal Squamous Cell Carcinoma.2022Disease markersFree full text
  9. Long non‑coding RNA PART1: dual role in cancer.2022Human cell
  10. SYNGR2 serves as a prognostic biomarker and correlates with immune infiltrates in esophageal squamous cell carcinoma.2022The journal of gene medicine
All its trials on ClinicalTrials.gov, any status2
  1. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT06010303Study sitePhase 2Start 2023-11
  2. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
More papers found outside PubMed (not counted)1
  1. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 45 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
45
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 7720222023: 101020232024: 7720242025: 15152025

2 hospitals in Lanzhou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Posted
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineRadiology / nuclear medicineMedical oncology
Papers it led45
  1. Whole-lesion iodine map histogram analysis combined with focal ROI iodine concentrations for preoperative prediction of cytokeratin 19-positive hepatocellular carcinoma.2026Abdominal radiology (New York)
  2. Deep learning 3D super-resolution radiomics model based on Gd-enhanced MRI for improving preoperative prediction of HCC pathological grading.2026Abdominal radiology (New York)
  3. Prediction of Posthepatectomy Liver Failure in Narrow Resection Margins HCC: A Model Based on Iodine Map Histogram Analysis of Nontumorous Liver Parenchyma.2025Academic radiology
  4. Comprehensive molecular characteristics of hepatocellular carcinoma based on multi-omics analysis.2025BMC cancerFree full text
  5. Visit‑to‑visit variability of inflammation-immunity indices and prognosis in hepatocellular carcinoma.2025BMC gastroenterologyFree full text
  6. Adherence to STARD guidelines in miRNA diagnostic accuracy studies for hepatocellular carcinoma: a systematic review.2025BMC medical research methodologyFree full text
  7. Study on the concordance in the diagnostic efficacy between CEUS LI-RADS and CT/MR LI-RADS for HCC.2025Clinical hemorheology and microcirculation
  8. Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets.2025Hepatology international
  9. APM-Related gene signature model to predict prognosis and immunotherapy response in hepatocellular carcinoma.2025Human genetics
  10. Therapeutic targets for hepatocellular carcinoma identified using proteomics and Mendelian randomization.2025Journal of gastroenterology and hepatology
  11. A spreadable self-gelling hemostatic powder sensitizes CAR-NK cell therapy to prevent hepatocellular carcinoma recurrence postresection.2025Journal of nanobiotechnologyFree full text
  12. Post-translational modifications in hepatocellular carcinoma: mechanisms and therapeutic potential.2025Medical oncology (Northwood, London, England)
  13. Causal relationship between serum bilirubin, cholelithiasis and hepatobiliary and pancreatic malignancy: A bidirectional and 2-sample Mendelian randomization study.2025MedicineFree full text
  14. A contrast‑enhanced CT histogram‑driven nomogram for predicting post‑radiotherapy liver regeneration in hepatocellular carcinoma.2025Radiation oncology (London, England)Free full text
  15. Integrating single-cell RNA sequencing, WGCNA, and machine learning to identify key biomarkers in hepatocellular carcinoma.2025Scientific reportsFree full text
  16. Progress of Pyruvate Kinase M2 in Hepatocellular Carcinoma-Associated Signaling Pathway.2025Tissue engineering. Part C, Methods
  17. P2RX4 promotes hepatocellular carcinoma progression via calcium-mediated PI3K/AKT activation and immune remodeling.2025World journal of surgical oncologyFree full text
  18. Alpha-fetoprotein upregulates hepatocellular carcinoma cell-intrinsic PD-1 expression through the LATS2/YAP/TEAD1 pathway.2024Biochimica et biophysica acta. General subjects
  19. The Role of Pyruvate Kinase M2 Posttranslational Modification in the Occurrence and Development of Hepatocellular Carcinoma.2024Cell biochemistry and function
  20. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.2024Journal for immunotherapy of cancerFree full text
  21. Prognostic Significance of Iron Metabolism and Immune-Related Genes as Risk Markers in Hepatocellular Carcinoma.2024Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  22. Integrative analysis of multi-omics data identified PLG as key gene related to Anoikis resistance and immune phenotypes in hepatocellular carcinoma.2024Journal of translational medicineFree full text
  23. Transarterial Chemoembolization Combined with Lenvatinib for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2024Oncology
  24. Identification and verification of a prognostic autophagy-related gene signature in hepatocellular carcinoma.2024Scientific reportsFree full text
  25. Different power modes of microwave ablation for hepatocellular carcinoma: Evaluation of recurrence rate and factors related to recurrence.2023Asian journal of surgery
  26. Development and validation of a coagulation-related genes prognostic model for hepatocellular carcinoma.2023BMC bioinformaticsFree full text
  27. MicroRNA-5195-3p mediated malignant biological behaviour of insulin-resistant liver cancer cells via SOX9 and TPM4.2023BMC cancerFree full text
  28. Predicting glypican-3 expression in hepatocellular carcinoma: A comprehensive analysis using combined contrast-enhanced ultrasound and clinical factors.2023Clinical hemorheology and microcirculation
  29. Neutrophil extracellular traps regulating tumorimmunity in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  30. Establishment and characterization of a new Chinese hepatocellular carcinoma cell line, Hep-X1.2023Human cell
  31. PA-MSHA Regulates PD-L1 Expression in Hepatoma Cells.2023Immunological investigations
  32. Predictive Roles of ADAM17 in Patient Survival and Immune Cell Infiltration in Hepatocellular Carcinoma.2023International journal of molecular sciencesFree full text
  33. RPS24 Is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma.2023International journal of molecular sciencesFree full text
  34. Contrast-enhanced ultrasound demonstrates greater adjuvant potential: past, current status, and future applications in Hepatocellular carcinoma early diagnosis.2023Medical ultrasonography
  35. BUB1 predicts poor prognosis and immune status in liver hepatocellular carcinoma.2022APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  36. Study on correlation between two-dimensional ultrasound, contrast-enhanced ultrasound and microvascular invasion in hepatocellular carcinoma.2022Clinical hemorheology and microcirculation
  37. Overexpression of Ribosomal Protein S6 Kinase A4 (RPS6KA4) Predicts a Poor Prognosis in Hepatocellular Carcinoma Patients: A Study Based on TCGA Samples.2022Combinatorial chemistry & high throughput screening
  38. Relationship between Intestinal Microflora and Hepatocellular Cancer Based on Gut-Liver Axis Theory.2022Contrast media & molecular imagingFree full text
  39. The effect of metformin usage on survival outcomes for hepatocellular carcinoma patients with type 2 diabetes mellitus after curative therapy.2022Frontiers in endocrinologyFree full text
  40. Anticancer Effect of Arbutin on Diethylnitrosamine-Induced Liver Carcinoma in Rats via the GRP and GADD Pathway.2022Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  41. Overexpressed PAQR4 predicts poor overall survival and construction of a prognostic nomogram based on PAQR family for hepatocellular carcinoma.2022Mathematical biosciences and engineering : MBE
  42. Bioinformatic Evidence Reveals that Cell Cycle Correlated Genes Drive the Communication between Tumor Cells and the Tumor Microenvironment and Impact the Outcomes of Hepatocellular Carcinoma.2021BioMed research internationalFree full text
  43. The lncRNA VPS9D1-AS1 Promotes Hepatocellular Carcinoma Cell Cycle Progression by Regulating the HuR/CDK4 Axis.2021DNA and cell biology
  44. The expression and clinical significance of TPM4 in hepatocellular carcinoma.2021International journal of medical sciencesFree full text
  45. Transcript levels of spindle and kinetochore-associated complex 1/3 as prognostic biomarkers correlated with immune infiltrates in hepatocellular carcinoma.2021Scientific reportsFree full text
Chinese-language papers (not in the count)1
  1. [Overexpression of Nei endonuclease VIII-like protein 3 in hepatocellular carcinoma indicates increased levels of immune infiltration and an unfavorable prognosis].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  2. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 108 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 1.1%.

Papers led
108
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 121220212022: 151520222023: 202020232024: 202020242025: 38382025

3 hospitals in Lanzhou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
    Phase
    Phase 3
    Started
    2025-02
    Posted
    Registry
    NCT06731478

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changzhou, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  2. Recruiting
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-04
    Posted
    Registry
    NCT06925243

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  3. Recruiting
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 3
    Started
    2025-05
    Posted
    Registry
    NCT06949033

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesGuangzhou, Lanzhou

  4. Recruiting
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT07029269

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Hangzhou, Lanzhou, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsImaging & AISurgery
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicineMedical oncology
Papers it led108
  1. The snoRNA SNORA21 promotes gastric tumorigenesis by attenuating P53 activity through CHK1 phosphorylation inhibition and PERP-dependent feedback loops.2026Cellular signalling
  2. TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer.2026International immunopharmacology
  3. The Value of Double Contrast-Enhanced Ultrasonography in the Differential Diagnosis of Gastric Submucosal Tumors and the Assessment of the Malignant Risk of Gastrointestinal Stromal Tumors.2026Seminars in ultrasound, CT, and MR
  4. Targeted Dual-Responsive Liposomes Co-Deliver Jolkinolide B and Ce6 to Synergistically Enhance the Photodynamic/Immunotherapy Efficacy in Gastric Cancer through the PANoptosis Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  5. Identification and prioritization of high-frequency biomarkers and therapeutic targets in gastric cancer trials.2025BMC cancerFree full text
  6. KLC3 drives gastric cancer progression by stabilizing SLC2A5 to activate MAPK signaling and promote epithelial-mesenchymal transition.2025BMC cancerFree full text
  7. Identification of multiomics and immune infiltration-associated biomarkers for early gastric cancer: a machine learning-based diagnostic model development study.2025BMC cancerFree full text
  8. Indocyanine Green-Labeled Antibody-NOTCH2 as a New Fluorescent Molecular Imaging Probe for Gastric Cancer.2025Bioconjugate chemistryFree full text
  9. Comparing Quality of Life for Billroth II With Braun Versus Uncut Roux-en-Y Reconstruction After Total Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Clinical Trial.2025Cancer control : journal of the Moffitt Cancer CenterRCTFree full text
  10. The Black Hole of Immune Checkpoint Blocking Therapy for Gastric Cancer: Hyperprogressive Disease.2025Cancer scienceFree full text
  11. ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation.2025Cell death & diseaseFree full text
  12. Identification and Validation of a Novel Prognostic Signature of Gastric Cancer Based on Seven Complement System-Related Genes: An Integrated Analysis.2025Critical reviews in eukaryotic gene expression
  13. Integrative Analysis Reveals Differential Characteristics of DDR1 Mutant and Wild-type Gastric Cancers and Constructs their Prediction Models.2025Current medicinal chemistry
  14. Evolving Landscape of HER2-Targeted Therapies for Gastric Cancer Patients.2025Current treatment options in oncology
  15. Association between different patterns of obesity and the short-term outcomes of gastric cancer surgery.2025European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)Free full text
  16. Nutritional status of early oral feeding for gastric cancer patients after laparoscopic total gastrectomy: A retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  17. Sequential HIPEC, Claudin18.2-targeted therapy, and CapeOx chemotherapy leading to resolution of peritoneal metastases and curative resection in gastric cancer: a case report and literature review.2025Frontiers in immunologyFree full text
  18. Deep learning and multi-omics reveal programmed cell death-associated diagnostic signatures and prognostic biomarkers in gastric cancer.2025Frontiers in immunologyFree full text
  19. Renal capsule patient-derived xenograft model for gastric cancer: establishment and MRI characterization.2025Frontiers in immunologyFree full text
  20. Targeting the BAG2/CHIP axis promotes gastric cancer apoptosis by blocking apoptosome assembly.2025Frontiers in immunologyFree full text
  21. HER2-positive gastric cancer: from targeted therapy to CAR-T cell therapy.2025Frontiers in immunologyFree full text
  22. Targeting Eg5 using Arry520 combats gastric cancer by inducing monopolar spindles.2025Gene
  23. Multi-omic analysis reveals the role of coagulation factor family genes and their predictive value for immune checkpoint inhibitors efficacy in gastric cancer.2025International journal of biological macromolecules
  24. Does ambient particulate matter 1 increase the risk of gastric cancer in the northwest of China?2025International journal of cancer
  25. Clinical application value of modified overlap anastomosis for Siewert type II and III adenocarcinoma of esophagogastric junction.2025Journal of cancer research and clinical oncologyFree full text
  26. Gastric cancer-derived exosomal let-7 g-5p mediated by SERPINE1 promotes macrophage M2 polarization and gastric cancer progression.2025Journal of experimental & clinical cancer research : CRFree full text
  27. Targeted DDR1 Treatment Strategy Enhances PD-1 Immunotherapy Efficacy against Gastric Cancer.2025Journal of medicinal chemistryFree full text
  28. Single-cell RNA sequencing and spatial transcriptomics reveal the heterogeneity and intercellular communication of cancer-associated fibroblasts in gastric cancer.2025Journal of translational medicineFree full text
  29. Neoadjuvant cadonilimab plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction adenocarcinoma: A multicenter, phase 2 study.2025Med (New York, N.Y.)
  30. Effect of PRKD3 on cell cycle in gastric cancer progression and downstream regulatory networks.2025Medical oncology (Northwood, London, England)
  31. Nanomaterials in gastric cancer: pioneering precision medicine for diagnosis, therapy, and prevention.2025Medical oncology (Northwood, London, England)
  32. ELK1 modulates SF3B3 transcriptional activity to stimulate proliferation and inhibit apoptosis in gastric cancer through the activation of the MAPK pathway.2025Neoplasma
  33. The impact of GST genetic polymorphisms on the response to oxaliplatin-based chemotherapy and survival prognosis in gastric cancer patients.2025Pharmacogenomics
  34. The expression of transmembrane channel-like 5 in gastric cancer and its impact on tumor progression.2025Scientific reportsFree full text
  35. SERPINE1 Facilitates Metastasis in Gastric Cancer Through Anoikis Resistance and Tumor Microenvironment Remodeling.2025Small (Weinheim an der Bergstrasse, Germany)
  36. A prospective and comparative study on improving the diagnostic accuracy of early gastric cancer based on deep convolutional neural network real-time diagnosis system (with video).2025Surgical endoscopy
  37. The role of TMEM119 in gastric adenocarcinoma and its specific effects on immunity.2025The Journal of international medical researchFree full text
  38. A case of neonatal gastric teratoma complicated with occult gastrointestinal hemorrhage misdiagnosed as lymphangioma.2025The Turkish journal of pediatrics
  39. The current landscape and advances in functional-preserving gastric cancer surgery.2025World journal of surgical oncologyFree full text
  40. Historical evolution and current research status of lymph node staging in gastric cancer: a review.2025World journal of surgical oncologyFree full text
  41. eIF6: a promising therapeutic target for gastric carcinoma via PI3K/AKT pathway modulation.2025World journal of surgical oncologyFree full text
  42. Combination of clinical and spectral-CT iodine concentration for predicting liver metastasis in gastric cancer: a preliminary study.2024Abdominal radiology (New York)
  43. Correlation of CT parameters and PD-L1 expression status in gastric cancer.2024Abdominal radiology (New York)
  44. Not all carotenoids can reduce the risk of gastric cancer: a systematic review with meta-analysis.2024BMC gastroenterologyFree full text
  45. Exploring the therapeutic potential of diterpenes in gastric cancer: Mechanisms, efficacy, and clinical prospects.2024Biomolecules & biomedicineFree full text
  46. Prediction of Ki-67 expression in gastric gastrointestinal stromal tumors using histogram analysis of monochromatic and iodine images derived from spectral CT.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  47. Targeting NUF2 suppresses gastric cancer progression through G2/M phase arrest and apoptosis induction.2024Chinese medical journalFree full text
  48. Current status of neoadjuvant immunotherapy for the treatment of gastric cancer.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  49. The application of organoids in cancers associated with pathogenic infections.2024Clinical and experimental medicineFree full text
  50. Whether the use of intravenous contrast-enhanced ultrasound can improve the accuracy of T stage diagnosis of gastric cancer?2024Clinical hemorheology and microcirculation
  51. Value of spectral CT parameters in predicting the efficacy of neoadjuvant chemotherapy for gastric cancer.2024Clinical radiology
  52. Prognostic Value and Therapeutic Significance of CCL Chemokines in Gastric Cancer.2024Current medicinal chemistry
  53. Mesenchymal Stem Cells Target Gastric Cancer and Deliver Epirubicin via Tunneling Nanotubes for Enhanced Chemotherapy.2024Current stem cell research & therapy
  54. IL-17A in gastric carcinogenesis: good or bad?2024Frontiers in immunologyFree full text
  55. SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report.2024Frontiers in immunologyFree full text
  56. UBE2L3 expression in human gastric cancer and its clinical significance.2024Journal of cancer research and clinical oncologyFree full text
  57. High expression of NOTCH2 in gastric adenocarcinoma: A novel early diagnostic target.2024Journal of gastroenterology and hepatology
  58. Biological Clock Genes are Crucial and Promising Biomarkers for the Therapeutic Targets and Prognostic Assessment in Gastric Cancer.2024Journal of gastrointestinal cancer
  59. MicroRNAs in Helicobacter pylori-infected gastric cancer: Function and clinical application.2024Pharmacological research
  60. Photodynamic therapy may salvage chemotherapy failure in gastric cancer: A case report and a literature review.2024Photodiagnosis and photodynamic therapy
  61. EGCG targeting STAT3 transcriptionally represses PLXNC1 to inhibit M2 polarization mediated by gastric cancer cell-derived exosomal miR-92b-5p.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  62. Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy.2023Abdominal radiology (New York)
  63. Risk of venous thromboembolism in patients undergoing gastric cancer surgery: a systematic review and meta-analysis.2023BMC cancerFree full text
  64. Glycosyltransferase GLT8D1 and GLT8D2 serve as potential prognostic biomarkers correlated with Tumor Immunity in Gastric Cancer.2023BMC medical genomicsFree full text
  65. Organoids: Construction and Application in Gastric Cancer.2023BiomoleculesFree full text
  66. PICH Activates Cyclin A1 Transcription to Drive S-Phase Progression and Chemoresistance in Gastric Cancer.2023Cancer research
  67. A novel adenosine signalling-based prognostic signature in gastric cancer and its association with cancer immune features and immunotherapy response.2023Cell biology international
  68. A nine-gene signature as prognostic biomarker in gastric cancer by bioinformatics analysis.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  69. Combined Inhibition of KIF11 and KIF15 as an Effective Therapeutic Strategy for Gastric Cancer.2023Current cancer drug targets
  70. Focusing on Helicobacter pylori infection in the elderly.2023Frontiers in cellular and infection microbiologyFree full text
  71. Photodynamic therapy improves the outcome of immune checkpoint inhibitors via remodelling anti-tumour immunity in patients with gastric cancer.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  72. Epidemiology, risk areas and macro determinants of gastric cancer: a study based on geospatial analysis.2023International journal of health geographicsFree full text
  73. Exploration of gastric carcinogenesis from the relationship between bile acids and intestinal metaplasia and intragastric microorganisms (H. pylori and non-H. pylori).2023Journal of cancer research and clinical oncologyFree full text
  74. A practical recurrence risk model based on Lasso-Cox regression for gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  75. STAT1 suppresses the transcriptional activity of TRIM21 in gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  76. Predictive value of 18F-FDG PET/CT multi-metabolic parameters and tumor metabolic heterogeneity in the prognosis of gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  77. The prognostic value of FAR and a novel FAR-CA125 score in resectable gastric signet ring cell carcinoma patients.2023Journal of cancer research and clinical oncologyFree full text
  78. Exploring the role of PMEPA1 in gastric cancer.2023Molecular and cellular probes
  79. Exploring the role of FBXO5 in gastric cancer.2023Molecular and cellular probes
  80. High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer.2023Pathology oncology research : PORFree full text
  81. Research progress of potential factors influencing photodynamic therapy for gastrointestinal cancer.2023Photodiagnosis and photodynamic therapy
  82. MKRN2 inhibits the proliferation of gastric cancer by downregulating PKM2.2022AgingFree full text
  83. Identification of differentially expressed miRNAs derived from serum exosomes associated with gastric cancer by microarray analysis.2022Clinica chimica acta; international journal of clinical chemistry
  84. Combination of clinical and spectral-CT parameters for predicting lymphovascular and perineural invasion in gastric cancer.2022Diagnostic and interventional imaging
  85. Meta-Analysis of Efficacy and Safety of Karelizumab Combined with Apatinib in the Treatment of Advanced Gastric Cancer.2022Disease markersFree full text
  86. The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer.2022Experimental cell research
  87. MCEMP1 is a potential therapeutic biomarker associated with immune infiltration in advanced gastric cancer microenvironment.2022Gene
  88. TCF7L2 promotes anoikis resistance and metastasis of gastric cancer by transcriptionally activating PLAUR.2022International journal of biological sciencesFree full text
  89. Measurement of soluble PD-1 and soluble PD-L1 as well as PD-L1 and PD-1 from perioperative patients with gastric carcinoma.2022Japanese journal of clinical oncology
  90. Long non-coding RNA TNK2 AS1/microRNA-125a-5p axis promotes tumor growth and modulated phosphatidylinositol 3 kinase/AKT pathway.2022Journal of gastroenterology and hepatology
  91. NCAPH regulates gastric cancer progression through DNA damage response.2022Neoplasma
  92. Photodynamic Therapy in Combination with Chemotherapy, Targeted, and Immunotherapy As a Successful Therapeutic Approach for Advanced Gastric Adenocarcinoma: A Case Report and Literature Review.2022Photobiomodulation, photomedicine, and laser surgery
  93. Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer.2022Science advancesFree full text
  94. Clinico-radiological nomogram for preoperatively predicting post-resection hepatic metastasis in patients with gastric adenocarcinoma.2022The British journal of radiologyRCTFree full text
  95. Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer.2022TheranosticsFree full text
  96. Study on the expression of c-Met in gastric cancer and its correlation with preoperative serum tumor markers and prognosis.2022World journal of surgical oncologyFree full text
  97. Immune Cell Landscape in Gastric Cancer.2021BioMed research internationalFree full text
  98. Long intergenic noncoding RNA00265 promotes proliferation of gastric cancer via the microRNA-144-3p/Chromobox 4 axis.2021BioengineeredFree full text
  99. Prognostic Value of lncRNA PVT1 for Patients with Gastric Cancer: A Meta-Analysis.2021Disease markersFree full text
  100. Construction and Validation of a Novel Prognostic Signature for Intestinal Type of Gastric Cancer.2021Disease markersFree full text
  101. Auditory and Visual Stimulation for Abdominal Postoperative Patients Experiencing Enhanced Recovery After Surgery (ERAS).2021Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and AssociatesRCT
  102. Prognostic Value of Combination of Inflammatory and Tumor Markers in Resectable Gastric Cancer.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  103. Damage Control Surgery Saves Patient with Gastric Lymphoma from Radical Gastrectomy.2021Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  104. Carcinosarcoma and sarcomatoid carcinoma of the stomach: Two case reports.2021MedicineFree full text
  105. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.2021Nature communicationsFree full text
  106. A novel UBE2T inhibitor suppresses Wnt/β-catenin signaling hyperactivation and gastric cancer progression by blocking RACK1 ubiquitination.2021OncogeneFree full text
  107. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.2021OncoimmunologyFree full text
  108. Evidence Mapping of Proton Therapy, Heavy Ion Therapy, and Helical Tomotherapy for Gastric Cancer.2021Oncology research and treatment
Chinese-language papers (not in the count)3
  1. Research progress in effects of MAGE-A family on gastric cancer.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciencesFree full text
  2. [Correlations of 18F-FDG PET/CT Metabolic Parameters and Metabolic Heterogeneity with Human Epidermal Growth Factor Receptor 2 Expression in Patients with Gastric Cancer].2022Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  3. [Spectral CT multi-parameter imaging in preoperatively evaluation the status of lymphovascular and perineural invasion of gastric cancer].2022Zhonghua yi xue za zhi
All its trials on ClinicalTrials.gov, any status14
  1. Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerRecruitingNCT06731478Study sitePhase 3Start 2025-02
  2. Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06949033Study sitePhase 3Start 2025-05
  3. Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric CancerRecruitingNCT07029269Study sitePhase 3Start 2025-06
  4. Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06925243Study sitePhase 3Start 2025-04
  5. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  6. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  7. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  8. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  9. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  10. A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric CarcinomaTerminatedNCT04718402Study sitePhase 1Start 2021-03
  11. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12
  12. Comparing the Prognosis of Patients With Cardia and Non-cardia Gastric Cancer.Status unknownNCT03895008Study siteStart 2019-07
  13. Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Study sitePhase 2/Phase 3Start 2019-12
  14. Dendritic Cell-based Immunotherapy in Treatment Gastric CancerStatus unknownNCT03410732Study sitePhase 2Start 2017-07

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 41 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
41
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 6620222023: 121220232024: 141420242025: 772025

3 hospitals in Lanzhou for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
    Phase
    Not given
    Started
    2025-04
    Posted
    Registry
    NCT06862869

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiangmen, Jinan, Lanzhou, Nanchang, Nanjing, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Taizhou, Wuhan, Wuxi, Xi'an, Yinchuan, Zhanjiang, Zunyi

  2. Recruiting
    D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06300177

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 63 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Nephrology
Papers it led41
  1. Predicting Durable Clinical Benefits of Postoperative Adjuvant Chemotherapy in Non-small Cell Lung Cancer: A Nomogram Based on CT Imaging and Immune Type.2025Academic radiology
  2. Machine learning-based prediction of invasiveness in lung adenocarcinoma presenting as ground-glass nodules using radiomics and clinical CT features.2025BMC cancerFree full text
  3. Lung cancer immunotherapy in 2025: where we stand and what comes next?2025Frontiers in immunologyFree full text
  4. Dissecting the intratumoral microbiome landscape in lung cancer.2025Frontiers in immunologyFree full text
  5. CircROBO2 Orchestrates Osimertinib Resistance Through miR-625-5p/PDGFB-Mediated MAPK Activation in Non-Small Cell Lung Cancer.2025IUBMB life
  6. Molecular mechanism of resveratrol in suppressing lung adenocarcinoma based on network pharmacology and molecular docking.2025MedicineFree full text
  7. Association between advanced lung cancer inflammation index and gallstone prevalence among U.S. adults: A population-based study.2025PloS oneFree full text
  8. Ultrasound-Responsive Nanocarriers Delivering siRNA and Fe3O4 Nanoparticles Reprogram Macrophages and Inhibit M2 Polarization for Enhanced NSCLC Immunotherapy.2024ACS applied materials & interfaces
  9. Histogram analysis of multiple diffusion models for predicting advanced non-small cell lung cancer response to chemoimmunotherapy.2024Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  10. Comparative analysis of three-dimensional and two-dimensional models for predicting the malignancy probability of subsolid nodules.2024Clinical radiology
  11. Added value of spectral computed tomography quantitative parameters for differentiating tuberculosis-associated fibrosing mediastinitis from endobronchial lung cancer: initial results.2024Clinical radiology
  12. Ultrasound-mediated PLGA-PEI Nanobubbles Carrying STAT6 SiRNA Enhances NSCLC Treatment via Repolarizing Tumor-associated Macrophages from M2 to M1 Phenotypes.2024Current drug delivery
  13. Whole-lesion iodine map histogram analysis versus single-slice spectral CT parameters for determining novel International Association for the Study of Lung Cancer grade of invasive non-mucinous pulmonary adenocarcinomas.2024Diagnostic and interventional imaging
  14. Ultrasound-mediated nanobubbles loaded with STAT6 siRNA inhibit TGF-β1-EMT axis in LUSC cells via overcoming the polarization of M2-TAMs.2024European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  15. Predicting lymphovascular invasion in N0 stage non-small cell lung cancer: A nomogram based on Dual-energy CT imaging and clinical findings.2024European journal of radiology
  16. DUS4L suppresses invasion and metastasis in LUAD via modulation of PI3K/AKT and ERK/MAPK signaling through GRB2.2024International immunopharmacology
  17. Ultrasound-responsive nanocarriers with siRNA and Fe3O4 regulate macrophage polarization and phagocytosis for augmented non-small cell lung cancer immunotherapy.2024Journal of nanobiotechnologyFree full text
  18. Evaluating Mediastinal Lymph Node Metastasis of Non-Small Cell Lung Cancer Using Mono-exponential, Bi-exponential, and Stretched-exponential Models of Diffusion-weighted Imaging.2024Journal of thoracic imaging
  19. CLIP170 inhibits the metastasis and EMT of papillary thyroid cancer through the TGF-β pathway.2024Medical oncology (Northwood, London, England)
  20. Knowledge, attitude, and practice of lung cancer screening and associated factors among high-risk population in Lanzhou, China: A cross-sectional study.2024MedicineFree full text
  21. Deep learning radiomics of multimodal ultrasound for classifying metastatic cervical lymphadenopathy into primary cancer sites: a feasibility study.2024Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  22. Renal metastasis from lung squamous-cell carcinoma: A case report.2023Asian journal of surgery
  23. Genomic and immunogenomic analysis of three prognostic signature genes in LUAD.2023BMC bioinformaticsFree full text
  24. cRGD-targeted gold-based nanoparticles overcome EGFR-TKI resistance of NSCLC via low-temperature photothermal therapy combined with sonodynamic therapy.2023Biomaterials science
  25. Contrast-enhanced ultrasound (CEUS) - A new tool for evaluating blood supply in primary peripheral lung cancer.2023Clinical hemorheology and microcirculation
  26. MRI features and whole-lesion apparent diffusion coefficient histogram analysis of brain metastasis from non-small cell lung cancer for differentiating epidermal growth factor receptor mutation status.2023Clinical radiology
  27. Ultrasound-mediated mesoporous silica nanoparticles loaded with PDLIM5 siRNA inhibit gefitinib resistance in NSCLC cells by attenuating EMT.2023European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  28. Role of iodine density value on dual-energy CT for detection of high tumor cell proportion region in lung cancer during CT-guided transthoracic biopsy.2023European journal of radiology
  29. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.2023Frontiers in immunologyFree full text
  30. Differentiating invasive thymic epithelial tumors from mediastinal lung cancer using spectral CT parameters.2023Japanese journal of radiology
  31. Echinocystic acid induces the apoptosis, and inhibits the migration and invasion of non-small cell lung cancer cells.2023Medical oncology (Northwood, London, England)
  32. Whole-tumor histogram analysis of multi-parametric MRI for differentiating brain metastases histological subtypes in lung cancers: relationship with the Ki-67 proliferation index.2023Neurosurgical review
  33. Melittin kills A549 cells by targeting mitochondria and blocking mitophagy flux.2023Redox report : communications in free radical researchFree full text
  34. Sensitive Interrogation of Enhancer Activity in Living Cells on a Nanoelectroporation-Probing Platform.2022ACS sensors
  35. Predictive value of multiple metabolic and heterogeneity parameters of 18F-FDG PET/CT for EGFR mutations in non-small cell lung cancer.2022Annals of nuclear medicine
  36. Ultrasound-sensitive siRNA-loaded nanobubbles fabrication and antagonism in drug resistance for NSCLC.2022Drug deliveryFree full text
  37. Pharmacological interventions for preventing atrial fibrillation after lung surgery: systematic review and meta-analysis.2022European journal of clinical pharmacology
  38. Melittin induces ferroptosis and ER stress-CHOP-mediated apoptosis in A549 cells.2022Free radical research
  39. Rare form of metastasis: lung cancer metastases to inguinal hernia sac detected by 18F-FDG PET/CT.2022Japanese journal of clinical oncology
  40. Relationship between epidermal growth factor receptor mutations and CT features in patients with lung adenocarcinoma.2021Clinical radiology
  41. Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.2021Journal of cancer research and clinical oncologyFree full text
Chinese-language papers (not in the count)9
  1. [Research Progress on the Regulatory Mechanism of Respiratory Microbiota in the 
Comorbidity of Chronic Obstructive Pulmonary Disease and Lung Cancer].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  2. [Predicting Invasive Non-mucinous Lung Adenocarcinoma IASLC Grading: 
A Nomogram Based on Dual-energy CT Imaging and Conventional Features].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  3. [Application Value of an AI-based Imaging Feature Parameter Model 
for Predicting the Malignancy of Part-solid Pulmonary Nodule].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  4. [A Case of Multiple Primary Pulmonary Neuroendocrine Carcinoma
with EML4-ALK Fusion Gene Positive].2025Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  5. [Advancements in Radiomics for Immunotherapy of Non-small Cell Lung Cancer].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  6. [Comparison of Short-term Efficacy of Neoadjuvant Immunotherapy Combined with Chemotherapy and Surgery Alone for Locally Advanced Resectable 
Non-small Cell Lung Cancer].2024Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  7. [Exploration of the Perturbation of PKIG in Lung Squamous Cell Carcinoma and the Role in Tumor Microenvironment Based on Bioinformatics Method].2023Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  8. [Application Value of Artificial Intelligence-assisted Three-dimensional Reconstruction in Planning Thoracoscopic Segmentectomy].2023Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
  9. [Clinical Study of Artificial Intelligence-assisted Diagnosis System in Predicting the 
Invasive Subtypes of Early-stage Lung Adenocarcinoma Appearing as Pulmonary Nodules].2022Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
All its trials on ClinicalTrials.gov, any status9
  1. Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant TherapyRecruitingNCT06862869Study siteStart 2025-04
  2. D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingNCT06300177Study sitePhase 3Start 2024-03
  3. A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid TumorsActive, not recruitingNCT07160335Study sitePhase 1Start 2025-09
  4. Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT07162883Study sitePhase 3Start 2025-11
  5. A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsStatus unknownNCT06469879Study sitePhase 3Start 2024-09
  6. Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.Status unknownNCT05922345Study sitePhase 3Start 2023-06
  7. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  8. A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Study sitePhase 3Start 2020-01
  9. Robot-Assisted vs. Video-Assisted Lobectomy for NSCLC (RAVAR)Active, not recruitingNCT06524427Study siteN/AStart 2020-08

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 46 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.8%.

Papers led
46
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 3320212022: 8820222023: 9920232024: 101020242025: 15152025

3 hospitals in Lanzhou for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
    Phase
    Phase 2/Phase 3
    Started
    2025-10
    Posted
    Registry
    NCT06989437

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Wenzhou, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineGastroenterology / hepatologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led46
  1. Efficacy and safety of PRRT for the treatment of pancreatic neuroendocrine tumors: Systematic review and meta-analysis.2026Bulletin du cancer
  2. Cyclin B2 facilitates glycolysis and tumor progression in pancreatic ductal adenocarcinoma by promoting histone lactylation.2025BMC cancerFree full text
  3. Curcumin Inhibits the Development of Pancreatic Cancer by Targeting the circ_0079440/miR-522-3p/EIF4A1 Pathway.2025Cell biochemistry and biophysics
  4. KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC.2025Cell reports. MedicineFree full text
  5. Elevated expression of transferrin receptor-1 in pancreatic cancer: clinical implications and prognostic significance.2025Clinical and experimental medicineFree full text
  6. Efficacy and safety of cadonilimab combined with AG chemotherapy in patients with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma: a retrospective real-world study.2025Frontiers in immunologyFree full text
  7. Reprogramming of glucose metabolism in pancreatic cancer: mechanisms, implications, and therapeutic perspectives.2025Frontiers in immunologyFree full text
  8. Pancreatic cancer subtyping - the keystone of precision treatment.2025Frontiers in immunologyFree full text
  9. Development and validation of a nomogram for a prognostic model for resected pancreatic ductal adenocarcinoma.2025Hepatobiliary & pancreatic diseases international : HBPD INT
  10. Polyphenol-based pH-responsive nanoparticles enhance chemo-immunotherapy in pancreatic cancer.2025Journal of controlled release : official journal of the Controlled Release Society
  11. MMP28 recruits M2-type tumor-associated macrophages through MAPK/JNK signaling pathway-dependent cytokine secretion to promote the malignant progression of pancreatic cancer.2025Journal of experimental & clinical cancer research : CRFree full text
  12. Glucose Metabolism Reprogramming of Immune Cells in the Microenvironment of Pancreatic and Hepatobiliary Cancers.2025Journal of gastroenterology and hepatology
  13. Effect of Donor and Acceptor on Improving the ROS Generation of Benzothiadiazole-Based Photosensitizers and Effective Photodynamic Therapy to Pancreatic Cancer Cells.2025Luminescence : the journal of biological and chemical luminescence
  14. Causal relationship between serum bilirubin, cholelithiasis and hepatobiliary and pancreatic malignancy: A bidirectional and 2-sample Mendelian randomization study.2025MedicineFree full text
  15. OCIAD2 as a novel prognostic and therapeutic biomarker for pancreatic cancer: A study based on transcriptomic signature and bioinformatics analysis.2025PLoS computational biologyFree full text
  16. DDR1 in pancreatic adenocarcinoma: unraveling the mechanisms of immune exclusion.2025Scandinavian journal of gastroenterology
  17. Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1.2024BMC cancerFree full text
  18. Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment.2024Cancer scienceFree full text
  19. Preoperative CT histogram analysis to predict the expression of Ki-67 in solid pseudopapillary tumours of the pancreas.2024Clinical radiology
  20. Self-assembled metal-polyphenolic based multifunctional nanomedicine to improve therapy treatment of pancreatic cancer by inhibition of glutamine metabolism.2024Colloids and surfaces. B, Biointerfaces
  21. Case report: Microsatellite instability-high pancreas adenosquamous carcinoma with postoperative liver metastasis recurrence treated with multimodality therapy achieving complete pathological response.2024Frontiers in immunologyFree full text
  22. Pancreatic ductal adenocarcinoma: CEUS characteristics are correlated with pathological findings and help predict early recurrence after resection.2024Journal of clinical ultrasound : JCU
  23. Targeting the mevalonate pathway enhances the efficacy of 5-fluorouracil by regulating pyroptosis.2024Medical oncology (Northwood, London, England)Free full text
  24. Pancreatic stellate cells: Key players in pancreatic health and diseases (Review).2024Molecular medicine reportsFree full text
  25. Ciprofol suppresses proliferation, invasion and migration of human pancreatic cancer cells.2024Pakistan journal of pharmaceutical sciences
  26. A novel multidrug-resistant cell line from a Chinese patient with pancreatic ductal adenocarcinoma.2024Scientific reportsFree full text
  27. Time trend of pancreatic cancer mortality in the Western Pacific Region: age-period-cohort analysis from 1990 to 2019 and forecasting for 2044.2023BMC cancerFree full text
  28. A Novel Cuproptosis-Associated Gene Signature to Predict Prognosis in Patients with Pancreatic Cancer.2023BioMed research internationalFree full text
  29. Role of contrast-enhanced ultrasound with time-intensity curve analysis for differentiating hypovascular solid pancreatic lesions.2023European radiology
  30. Integrated transcriptomics, proteomics and metabolomics-based analysis uncover TAM2-associated glycolysis and pyruvate metabolic remodeling in pancreatic cancer.2023Frontiers in immunologyFree full text
  31. Targeting UBE2T Potentiates Gemcitabine Efficacy in Pancreatic Cancer by Regulating Pyrimidine Metabolism and Replication Stress.2023Gastroenterology
  32. Research trends on immunotherapy for pancreatic cancer: A bibliometric analysis.2023Human vaccines & immunotherapeuticsFree full text
  33. The Global, Regional and National Burden of Pancreatic Cancer Attributable to Smoking, 1990 to 2019: A Systematic Analysis from the Global Burden of Disease Study 2019.2023International journal of environmental research and public healthFree full text
  34. Integration of Single-Cell RNA Sequencing and Bulk RNA Sequencing Reveals That TAM2-Driven Genes Affect Immunotherapeutic Response and Prognosis in Pancreatic Cancer.2023International journal of molecular sciencesFree full text
  35. Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer.2023Oncology researchFree full text
  36. A nomogram for predicting survival in patients with advanced (stage III/IV) pancreatic body tail cancer: a SEER-based study.2022BMC gastroenterologyFree full text
  37. STAT3 Inhibitors: A Novel Insight for Anticancer Therapy of Pancreatic Cancer.2022BiomoleculesFree full text
  38. Understanding Necroptosis in Pancreatic Diseases.2022BiomoleculesFree full text
  39. Nonhypovascular pancreatic ductal adenocarcinomas: CEUS imaging findings and differentiation from other types of solid pancreatic lesions.2022Clinical hemorheology and microcirculation
  40. Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression.2022Frontiers in immunologyFree full text
  41. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.2022Frontiers in immunologyFree full text
  42. Insulin receptor tyrosine kinase substrate (IRTKS) promotes the tumorigenesis of pancreatic cancer via PI3K/AKT signaling.2022Human cell
  43. Minimal apparent diffusion coefficient in predicting the Ki-67 proliferation index of pancreatic neuroendocrine tumors.2022Japanese journal of radiology
  44. Advances and challenges of neoadjuvant therapy in pancreatic cancer.2021Asia-Pacific journal of clinical oncology
  45. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.2021BMC cancerFree full text
  46. Single-cell RNA-seq reveals invasive trajectory and determines cancer stem cell-related prognostic genes in pancreatic cancer.2021BioengineeredFree full text
Chinese-language papers (not in the count)1
  1. [Establishment and identification of organoid derived from patients with pancreatic cancer based on suspension culture].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status3
  1. A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and FatigueRecruitingNCT06989437Study sitePhase 2/Phase 3Start 2025-10
  2. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
  3. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901CompletedNCT04805307Study sitePhase 1Start 2020-12

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 17 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
17
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 3320232024: 7720242025: 222025

2 hospitals in Lanzhou for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
    Phase
    Phase 3
    Started
    2024-03
    Posted
    Registry
    NCT06314906

    Age 18 years to 75 years (registered criteria)

    Led by Lanzhou University Second HospitalLanzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led17
  1. A Case of Ultrasound Findings in Male Encapsulated Papillary Carcinoma of the Breast.2026Journal of clinical ultrasound : JCU
  2. Targeting UBE2T suppresses breast cancer stemness through CBX6-mediated transcriptional repression of SOX2 and NANOG.2025Cancer letters
  3. Predictive Analysis of Neoadjuvant Chemotherapy Efficacy in Breast Cancer Using Multi-Region Ultrasound Imaging Features Combined With Pathological Parameters.2025Ultrasound in medicine & biology
  4. Incidence and risk factors of pain following breast cancer surgery: a retrospective national inpatient sample database study.2024BMC women's healthFree full text
  5. Targeting SHCBP1 Inhibits Tumor Progression by Restoring Ciliogenesis in Ductal Carcinoma.2024Cancer research
  6. Predictive value for axillary lymph node metastases in early breast cancer: Based on contrast-enhanced ultrasound characteristics of the primary lesion and sentinel lymph node.2024Clinical hemorheology and microcirculation
  7. The value of Demetics ultrasound-assisted diagnosis system in diagnosis of breast lesions and in assessment Ki-67 status of breast cancer.2024Journal of clinical ultrasound : JCU
  8. Ultrasound nanodroplets loaded with Siglec-G siRNA and Fe3O4 activate macrophages and enhance phagocytosis for immunotherapy of triple-negative breast cancer.2024Journal of nanobiotechnologyFree full text
  9. The Value of Percutaneous Contrast-Enhanced Ultrasound in Sentinel Lymph Node Identification, Metastatic Status and Burden Diagnosis in Early Breast Cancer.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  10. Combination of IVIM with DCE-MRI for diagnostic and prognostic evaluation of breast cancer.2024Magnetic resonance imaging
  11. Evaluating Tumor-Infiltrating Lymphocytes in Breast Cancer: The Role of Conventional Ultrasound and Contrast-Enhanced Ultrasound.2023Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  12. Ultrasound features combined with tumor-infiltrating lymphocytes for prediction of pathological response to neoadjuvant chemotherapy in breast cancer.2023Medical ultrasonography
  13. Evaluation of Breast Cancer Tumor-Infiltrating Lymphocytes on Ultrasound Images Based on a Novel Multi-Cascade Residual U-Shaped Network.2023Ultrasound in medicine & biology
  14. Predictive value of combining clinicopathological, multimodal ultrasonic characteristics in axillary lymph nodal metastasis burden of patients with cT1-2N0 breast cancer.2022Clinical hemorheology and microcirculation
  15. A preoperative nomogram for predicting the risk of sentinel lymph node metastasis in patients with T1-2N0 breast cancer.2022Japanese journal of radiology
  16. Identifying breast cancer subtypes associated modules and biomarkers by integrated bioinformatics analysis.2021Bioscience reportsFree full text
  17. Effect of Taijiquan assisted rehabilitation for breast cancer patients: A protocol for systematic review and meta-analysis.2021MedicineFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast CancerRecruitingNCT06314906Lead (inferred)Phase 3Start 2024-03
  2. To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast CancerActive, not recruitingNCT05365178Study sitePhase 3Start 2022-07

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 52 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.7%.

Papers led
52
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 8820222023: 121220232024: 131320242025: 14142025

1 hospital in Lanzhou for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurosurgeryNeurologySurgery (general/hepatobiliary/pancreatic)
Papers it led52
  1. Time-dependent diffusion MRI-based microstructural mapping for predicting IDH mutation status in glioma: A multicenter study.2026Magnetic resonance imaging
  2. Integrative machine learning and bioinformatics analysis unveil key genes for precise glioma classification and prognosis evaluation.2025Computational biology and chemistry
  3. Polymeric Polylactic Acid-Glycolic Acid-Based Nanoparticles Deliver Nintedanib Across the Blood-Brain Barrier to Inhibit Glioblastoma Growth.2025International journal of molecular sciencesFree full text
  4. Glioblastoma- derived exosomes (GBM-Exo) regulate microglial M2 polarization via the RAC1/AKT/NRF2 pathway.2025Journal of neuro-oncology
  5. Predicting telomerase reverse transcriptase promoter mutation status in glioblastoma by whole-tumor multi-sequence magnetic resonance texture analysis.2025Magnetic resonance imaging
  6. Deep learning radiomics nomograms predict Isocitrate dehydrogenase (IDH) genotypes in brain glioma: A multicenter study.2025Magnetic resonance imaging
  7. KCNE3 Facilitates M1 Macrophage Polarization by Suppressing the Wnt/β-Catenin Pathway, Inhibiting Glioma Proliferation, Migration, and Invasion.2025Molecular carcinogenesis
  8. MRI histogram and Visually AcceSAble Rembrandt Images features nomogram to predict PD-L1 levels in glioblastoma.2025Neurosurgical review
  9. Transitioning from molecular methods to therapeutic methods: An in‑depth analysis of glioblastoma (Review).2025Oncology reportsFree full text
  10. A comprehensive analysis of transcription factors identified TCF3 as a prognostic target for glioma.2025Scientific reportsFree full text
  11. CA3 bridges dietary restriction to glioblastoma suppression and tumor progression as a key downstream effector.2025Scientific reportsFree full text
  12. Molecular typing of gliomas on the basis of integrin family genes and a functional study of ITGA7.2025Scientific reportsFree full text
  13. Magnetic resonance imaging-based radiomics for predicting infiltration levels of CD68+ tumor-associated macrophages in glioblastomas.2025Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  14. Integrated MRI radiomics, tumor microenvironment, and clinical risk factors for improving survival prediction in patients with glioblastomas.2025Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  15. The Role of Chaf1b in Maintaining Glioma Stem Cell Stemness and Regulating Microglial Polarization.2025The Journal of neuroscience : the official journal of the Society for NeuroscienceFree full text
  16. Vasari-Based Features Nomogram to Predict the Tumor-Infiltrating CD8+ T Cell Levels in Glioblastoma.2024Academic radiology
  17. The role of apparent diffusion coefficient in the grading of adult isocitrate dehydrogenase-mutant astrocytomas: relationship with the Ki-67 proliferation index.2024Acta radiologica (Stockholm, Sweden : 1987)
  18. The mechanism of extracellular CypB promotes glioblastoma adaptation to glutamine deprivation microenvironment.2024Cancer letters
  19. Knockdown of trem2 promotes proinflammatory microglia and inhibits glioma progression via the JAK2/STAT3 and NF-κB pathways.2024Cell communication and signaling : CCSFree full text
  20. Amantadine against glioma via ROS-mediated apoptosis and autophagy arrest.2024Cell death & diseaseFree full text
  21. Distinguishment between high-grade gliomas and solitary brain metastases in peritumoural oedema: quantitative analysis using synthetic MRI at 3 T.2024Clinical radiology
  22. CircVCAN promotes glioma progression through the miR-488-3p/MEF2C-JAGGED1 axis.2024Environmental toxicology
  23. Neutrophils in glioma microenvironment: from immune function to immunotherapy.2024Frontiers in immunologyFree full text
  24. Bisphenol A: Unveiling Its Role in Glioma Progression and Tumor Growth.2024International journal of molecular sciencesFree full text
  25. Tumor-derived extracellular vesicles: how they mediate glioma immunosuppression.2024Molecular biology reports
  26. Whole-tumor histogram analysis of postcontrast T1-weighted and apparent diffusion coefficient in predicting the grade and proliferative activity of adult intracranial ependymomas.2024Neuroradiology
  27. Prediction of O(6)-methylguanine-DNA methyltransferase promoter methylation status in IDH-wildtype glioblastoma using MRI histogram analysis.2024Neurosurgical review
  28. Exploring the therapeutic mechanisms and prognostic targets of Biochanin A in glioblastoma via integrated computational analysis and in vitro experiments.2024Scientific reportsFree full text
  29. Efficacy of TTFields in high-grade gliomas: a protocol for systematic review and meta-analysis.2023BMJ openFree full text
  30. Diagnostic value of PET with different radiotracers and MRI for recurrent glioma: a Bayesian network meta-analysis.2023BMJ openFree full text
  31. Mitochondrial subtype MB-G3 contains potential novel biomarkers and therapeutic targets associated with prognosis of medulloblastoma.2023Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  32. Differentiating between adult intracranial medulloblastoma and ependymoma using MRI.2023Clinical radiology
  33. PLEKHA4 promotes glioblastoma progression through apoptosis inhibition, tumor cell migration, and macrophage infiltration.2023Immunobiology
  34. Circ_103128 is associated with the tumorigenesis of medulloblastoma.2023Journal of cancer research and clinical oncologyFree full text
  35. Quantitation of macropinocytosis in glioblastoma based on high-content analysis.2023Journal of neuroscience methods
  36. CircRNA-104718 promotes glioma malignancy through regulation of miR-218-5p/HMGB1 signalling pathway.2023Metabolic brain disease
  37. EEF1E1 promotes glioma proliferation by regulating cell cycle through PTEN/AKT signaling pathway.2023Molecular carcinogenesis
  38. MRI histogram analysis of tumor-infiltrating CD8+ T cell levels in patients with glioblastoma.2023NeuroImage. ClinicalFree full text
  39. Assessment of Ki-67 expression levels in IDH-wildtype glioblastoma using logistic regression modelling of VASARI features.2023Neurosurgical review
  40. Apparent diffusion coefficient values effectively predict cell proliferation and determine oligodendroglioma grade.2023Neurosurgical review
  41. CCNB2 is a novel prognostic factor and a potential therapeutic target in low-grade glioma.2022Bioscience reportsFree full text
  42. A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.2022Frontiers in immunologyFree full text
  43. Expressions and significances of CTSL, the target of COVID-19 on GBM.2022Journal of cancer research and clinical oncologyFree full text
  44. Treatment Response and Prognosis Evaluation in High-Grade Glioma: An Imaging Review Based on MRI.2022Journal of magnetic resonance imaging : JMRI
  45. CircTCF25 serves as a sponge for miR-206 to support proliferation, migration, and invasion of glioma via the Jak2/p-Stat3/CypB axis.2022Molecular carcinogenesis
  46. Biochanin A Sensitizes Glioblastoma to Temozolomide by Inhibiting Autophagy.2022Molecular neurobiology
  47. Correlation analysis of tumor purity with clinicopathological, molecular, and imaging features in high-grade gliomas.2022Neurosurgical review
  48. A Nomogram for Predicting Early Recurrence in Patients with High-Grade Gliomas.2022World neurosurgery
  49. Evaluation of the anti-angiogenic effect of bevacizumab on rat C6 glioma by spectral computed tomography.2021Acta radiologica (Stockholm, Sweden : 1987)
  50. UBE2R2-AS1 Inhibits Xenograft Growth in Nude Mice and Correlates with a Positive Prognosis in Glioma.2021Journal of molecular neuroscience : MN
  51. Apparent Diffusion Coefficient to Evaluate Adult Intracranial Ependymomas: Relationship to Ki-67 Proliferation Index.2021Journal of neuroimaging : official journal of the American Society of Neuroimaging
  52. Differentiating Giant Cell Glioblastoma from Classic Glioblastoma With Diffusion-Weighted Imaging.2021World neurosurgery
All its trials on ClinicalTrials.gov, any status3
  1. 3D-ASL and TDD-MRI for True Progression and Pseudoprogression After Glioma SurgeryActive, not recruitingNCT07687277Lead sponsorStart 2024-03
  2. Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion Imaging in GlioblastomaCompletedNCT06600399Lead sponsorStart 2022-10
  3. Newly Diagnosed GlioblastomaActive, not recruitingNCT04959500Study sitePhase 2Start 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Lanzhou for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 15 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 5520222023: 2220232024: 3320242025: 332025

7 hospitals in Lanzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led15
  1. Long non-coding RNA BCAR4 regulates osteosarcoma progression by targeting microRNA-1260a.2025Bulletin du cancer
  2. Thermo-responsive nano-hydrogel-based delivery of Saikosaponin a to enhance anti-PD-1 therapy in osteosarcoma.2025Nanomedicine (London, England)Free full text
  3. PDK1, associated with glycolytic metabolism, is a potential prognostic biomarker in osteosarcoma.2025PloS oneFree full text
  4. The Role of Ubiquitination in Osteosarcoma Development and Therapies.2024BiomoleculesFree full text
  5. Ferroptosis defense mechanisms: The future and hope for treating osteosarcoma.2024Cell biochemistry and function
  6. Circ_0004674 regulation of glycolysis and proliferation mechanism of osteosarcoma through miR-140-3p/TCF4 pathway.2024Journal of biochemical and molecular toxicology
  7. Silencing circular RNA hsa_circABCC1 inhibits osteosarcoma progression through down-regulating HDAC4 via sponging miR-591.2023Environmental toxicology
  8. Research Progress of Nanomaterials in Chemotherapy of Osteosarcoma.2023Orthopaedic surgeryFree full text
  9. The value of Ki-67 as a prognostic biomarker in osteosarcoma: A systematic review and meta-analysis.2022Asian journal of surgery
  10. Extraosseous Ewing's sarcoma/peripheral primitive neuroectodermal tumour of the kidney: a case report and literature review.2022BMC urologyFree full text
  11. Roles of MET in human cancer.2022Clinica chimica acta; international journal of clinical chemistry
  12. KMT5A Knockdown Suppresses Osteosarcoma Cell Proliferation and Metastasis Through Ꞵ-Catenin Signalling.2022Clinical and investigative medicine. Medecine clinique et experimentale
  13. TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells.2022Molecular biology reports
  14. Comparative analysis of magnetic resonance imaging and pathological findings of microcystic meningioma and meningeal Ewing sarcoma/peripheral primitive neuroectodermal tumors.2021Acta neurologica Belgica
  15. Exosomal miR-21-5p derived from bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion by targeting PIK3R1.2021Journal of cellular and molecular medicineFree full text
Earlier papers (2016–2020)9
  1. Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma.2020Molecular medicine reports
  2. Silencing of RIPK4 inhibits epithelial‑mesenchymal transition by inactivating the Wnt/β‑catenin signaling pathway in osteosarcoma.2020Molecular medicine reports
  3. Rosmarinic acid exerts an anticancer effect on osteosarcoma cells by inhibiting DJ-1 via regulation of the PTEN-PI3K-Akt signaling pathway.2020Phytomedicine : international journal of phytotherapy and phytopharmacology
  4. HOXA5 overexpression promotes osteosarcoma cell apoptosis through the p53 and p38α MAPK pathway.2019Gene
  5. COX‑2 promotes epithelial‑mesenchymal transition and migration in osteosarcoma MG‑63 cells via PI3K/AKT/NF‑κB signaling.2019Molecular medicine reports
  6. WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway.2018Cell biology international
  7. Pelargonidin induces antitumor effects in human osteosarcoma cells via autophagy induction, loss of mitochondrial membrane potential, G2/M cell cycle arrest and downregulation of PI3K/AKT signalling pathway.2018Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  8. Exosomes Derived from Human Bone Marrow Mesenchymal Stem Cells Promote Tumor Growth Through Hedgehog Signaling Pathway.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
  9. Long Noncoding RNA GAS5 Suppresses Cell Growth and Epithelial-Mesenchymal Transition in Osteosarcoma by Regulating the miR-221/ARHI Pathway.2017Journal of cellular biochemistry

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 5 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 1.0%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 112025

3 hospitals in Lanzhou for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Lanzhou for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Lanzhou for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 12 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.7%.

Papers led
12
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 2220232024: 2220242025: 442025

3 hospitals in Lanzhou for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Posted
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskBispecific & antibody drugs
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineMedical oncologyGastroenterology / hepatology
Papers it led12
  1. Analysis of discordant results in multi-technique platform-based MRD detection in multiple myeloma and the clinical decision-making dilemma.2026Leukemia & lymphoma
  2. Magnetic resonance imaging-based nomograms predict high-risk cytogenetic abnormalities in multiple myeloma: a two-centre study.2025Clinical radiology
  3. Efficacy and Safety of triplet versus doublet regimens in patients with multiple myeloma: A systematic review and meta-analysis.2025Current problems in cancer
  4. Threonine and tyrosine kinase promotes multiple myeloma progression by regulating regucalcin expression.2025Experimental cell research
  5. Peroxiredoxins as novel indicators in multiple myeloma associated with ferroptosis and immune infiltration.2025Scientific reportsFree full text
  6. Construction of the prediction model for multiple myeloma based on machine learning.2024International journal of laboratory hematology
  7. Elevated programmed cell death-1 protein/ligand (PD-1/PD-L1) and variants are associated with susceptibility to multiple myeloma: a case-control study in the Chinese cohort.2024Nucleosides, nucleotides & nucleic acids
  8. LGR4 promotes tumorigenesis by activating TGF-β1/Smad signaling pathway in multiple myeloma.2023Cellular signalling
  9. Obesity as a risk factor for multiple myeloma: insight on the role of adipokines.2023Pathology oncology research : PORFree full text
  10. The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.2022Frontiers in immunologyFree full text
  11. Nontargeted and targeted metabolomics approaches reveal the key amino acid alterations involved in multiple myeloma.2022PeerJFree full text
  12. Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)6
  1. [Prognosis and immune biomarkers of multiple myeloma].2024Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. [Prognostic Value of A New Risk Stratification Model (R2-ISS) in Newly Diagnosed Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  3. [A Prognostic Nomogram Based on Response to Bortezomib and BTK Expression for Treatment-Experienced Multiple Myeloma Patients].2022Zhongguo shi yan xue ye xue za zhi
  4. [Clinical Significance of sFLC/MP Level and Light Chain Escape in Patients with Multiple Myeloma Relapse].2021Zhongguo shi yan xue ye xue za zhi
  5. [The Influence of CONUT Score on the Prognosis of Patients with Multiple Myeloma].2021Zhongguo shi yan xue ye xue za zhi
  6. [Multiple myeloma with multiple extramedullary lesions of pancreas, stomach and skin: a case report].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  2. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 16 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 3320222023: 3320232024: 4420242025: 222025

4 hospitals in Lanzhou for lymphoma199 hospitals in China for lymphoma

No open trial on lymphoma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineENT / head & neck surgerySurgery (general/hepatobiliary/pancreatic)Neurology
Papers it led16
  1. The expression and significance of CXCL13 and CXCR5 in the tumor microenvironment of primary central nervous system diffuse large B-cell lymphoma.2026Free radical biology & medicine
  2. Targeting PD-L1 for PCNS-DLBCL: from molecular effects to clinical translation.2025Frontiers in immunologyFree full text
  3. CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges.2025Leukemia & lymphoma
  4. Recent advances in CD5+ diffuse large B-cell lymphoma.2024Annals of hematology
  5. Role and application of chemokine CXCL13 in central nervous system lymphoma.2024Annals of hematology
  6. Tumor microenvironment in primary central nervous system lymphoma (PCNSL).2024Cancer biology & therapyFree full text
  7. The prognostic value of CD8+ CTLs, CD163+ TAMs, and PDL1 expression in the tumor microenvironment of primary central nervous system lymphoma.2024Leukemia & lymphoma
  8. What factors are associated with the prognosis of primary testicular diffuse large B-cell lymphoma? A study based on the SEER database.2023Journal of cancer research and clinical oncologyFree full text
  9. Salinomycin sodium exerts anti diffuse large B-cell lymphoma activity through inhibition of LRP6-mediated Wnt/β-catenin and mTORC1 signaling.2023Leukemia & lymphoma
  10. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.2023World neurosurgery
  11. Report of penis lymphoma and review of the literature.2022Asian journal of surgery
  12. Deep learning radiomics of dual-modality ultrasound images for hierarchical diagnosis of unexplained cervical lymphadenopathy.2022BMC medicineFree full text
  13. Primary large B-cell lymphoma of the central nervous system with positive NMDAR antibody: a case report.2022BMC neurologyFree full text
  14. Chidamide induces long-term remission in rare subcutaneous panniculitis-like T-cell lymphoma: An unusual case report and literature review.2021International journal of immunopathology and pharmacologyFree full text
  15. Primary sacral lymphoma with multiple bone involvement evaluated using 18F-FDG PET/CT.2021Japanese journal of clinical oncology
  16. Damage Control Surgery Saves Patient with Gastric Lymphoma from Radical Gastrectomy.2021Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
Chinese-language papers (not in the count)4
  1. [Whole Exome Sequencing Reveals Gene Mutation Characteristics of Primary Central Nervous System Lymphoma].2024Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Features and Prognostic of Patients with Primary Central Nervous System Lymphoma].2024Zhongguo shi yan xue ye xue za zhi
  3. [Extranodal NK/T cell lymphoma, nasal type involving the larynx and digestive tract: a case report and literature review].2023Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgeryFree full text
  4. [The Prognostic Value of Prognostic Nutritional Index Combined with D-dimer in Patients with Diffuse Large B-Cell Lymphoma].2023Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status4
  1. Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05479994Study sitePhase 2Start 2022-10
  2. ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLStatus unknownNCT04578613Study sitePhase 3Start 2021-01
  3. A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)Status unknownNCT04398953Study sitePhase 2Start 2020-07
  4. A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)CompletedNCT03797456Study sitePhase 2Start 2019-04

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 2 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

1 hospital in Lanzhou for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & look-alikesKidney, retroperitoneum & vesselsTreatment & relapse

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 2 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

1 hospital in Lanzhou for myasthenia gravis89 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPregnancy, children, older adults
Departments in papersNeurology
Papers it led2
  1. Autoimmune polyendocrine syndrome type 2 in children: a case report and literature review.2025BMC pediatricsFree full text
  2. Wernicke encephalopathy, myasthenia gravis, or both?2022Panminerva medica
All its trials on ClinicalTrials.gov, any status1
  1. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 13 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.2%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 4420232024: 4420242025: 112025

2 hospitals in Lanzhou for coronary heart disease231 hospitals in China for coronary heart disease

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07521007

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  2. Not yet recruiting
    Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
    Phase
    N/A
    Started
    2021-09
    Posted
    Registry
    NCT04995159

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 67 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Harbin, Hefei, Huai'an, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shantou, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Yinchuan, Zhanjiang, Zhengzhou, Zhongshan, Zhuhai, Zibo

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicineNeurology
Papers it led13
  1. Different plaque types and its association with the volume and attenuation of pericoronary adipose tissue as assessed by coronary computed tomography angiography.2025Clinical radiology
  2. Association between Pericoronary Fat Attenuation Index Values and Plaque Composition Volume Fraction Measured by Coronary Computed Tomography Angiography.2024Academic radiology
  3. Relationship between pericoronary fat-attenuation values quantified by coronary computed tomography angiography and coronary artery disease severity.2024Clinical radiology
  4. MRI Diagnosis of Coronary Artery Lesions in Children With Kawasaki Disease and Their Correlation With Inflammatory Factors.2024Journal of magnetic resonance imaging : JMRI
  5. Differentiation of acute coronary syndrome with radiomics of pericoronary adipose tissue.2024The British journal of radiologyFree full text
  6. Association between endothelin-1, nitric oxide, and Gensini score in chronic coronary syndrome.2023BMC cardiovascular disordersFree full text
  7. Development of a nomogram based on pericoronary adipose tissue histogram parameters to differentially diagnose acute coronary syndrome.2023Clinical imaging
  8. Pericoronary adipose tissue differences among plaque types: a retrospective assessment.2023Clinical imaging
  9. Correlation of pericoronary adipose tissue CT attenuation values of plaques and periplaques with plaque characteristics.2023Clinical radiology
  10. Role of bilirubin in the prognosis of coronary artery disease and its relationship with cardiovascular risk factors: a meta-analysis.2022BMC cardiovascular disordersFree full text
  11. Correlation Between the MTHFR C677T Genotype and Coronary Heart Disease in Populations from Gansu, China.2022DNA and cell biology
  12. What is the real predictor of coronary artery calcification in patients with chronic kidney disease?2022Renal failureFree full text
  13. The Association of Morning Surge and Night-Time Dipping Blood Pressure with Significant and Complex Coronary Artery Lesions.2021High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension
All its trials on ClinicalTrials.gov, any status5
  1. A Phase 2b Clinical Trial of YN001 in Adults With Coronary AtherosclerosisRecruitingNCT07521007Study sitePhase 2Start 2026-07
  2. Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS SystemNot yet recruitingNCT04995159Study siteN/AStart 2021-09
  3. Efficacy and Safety of Colchicine After PCIActive, not recruitingNCT06472908Study sitePhase 3Start 2024-07
  4. Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki DiseaseCompletedNCT04078568Study sitePhase 3Start 2020-01
  5. Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast MediumCompletedNCT03671603Study siteStart 2018-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led 4 of the 2,604 English-language PubMed papers on congenital heart disease with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 1120242025: 002025

4 hospitals in Lanzhou for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Scoliosis

脊柱侧弯

Led 9 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 1.0%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 2220232024: 1120242025: 332025

2 hospitals in Lanzhou for scoliosis107 hospitals in China for scoliosis

No open trial on scoliosis lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Papers it led9
  1. The application of a functional-anatomical model in pulmonary risk assessment for adolescent idiopathic scoliosis.2026European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  2. Comparative efficacy and safety of high-dose versus low-dose tranexamic acid in adolescent idiopathic scoliosis: A systematic review and meta-analysis.2025PloS oneFree full text
  3. Establishment of a Rabbit Model of Rib Tethering-induced Early-onset Scoliosis: Insights into Lung Evaluation Using Design-based Stereology.2025Spine
  4. Research on Optimizing Early-Onset Scoliosis Correction Strategies Using Robotic Navigation Technology.2025World neurosurgery
  5. Effectiveness and Safety of High-Dose Tranexamic Acid in Adolescent Idiopathic Scoliosis Surgery: A Meta-Analysis and Systematic Review.2024World neurosurgery
  6. Evaluation of Chêneau brace in the treatment of thoracic and lumbar adolescent idiopathic scoliosis with apical vertebral rotation.2023Journal of back and musculoskeletal rehabilitation
  7. Effects of spinal deformities on lung development in children: a review.2023Journal of orthopaedic surgery and researchFree full text
  8. Postoperative changes in rib cage deviation in adolescent idiopathic scoliosis.2022Journal of back and musculoskeletal rehabilitation
  9. Treatment of Severe Congenital Scoliosis with Type ІI Respiratory Failure.2022Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

1 hospital in Lanzhou for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Lanzhou for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Chinese-language papers (not in the count)1
  1. [A case of Takayasu arteritis complicated with cavernous sinus syndrome presenting as unilateral optic nerve DWI hyperintensity].2024[Zhonghua yan ke za zhi] Chinese journal of ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led no English-language PubMed papers on idiopathic pulmonary fibrosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Lanzhou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Progress in sleep-disordered breathing in idiopathic pulmonary fibrosis].2017Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Lanzhou for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

3 hospitals in Lanzhou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Lanzhou for Gaucher disease40 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher DiseaseCompletedNCT05529992Study sitePhase 3Start 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution

1 hospital in Lanzhou for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    Phase
    Phase 3
    Started
    2023-02
    Posted
    Registry
    NCT05751967

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status2
  1. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary CholangitisRecruitingNCT05751967Study sitePhase 3Start 2023-02
  2. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisActive, not recruitingNCT06174402Study sitePhase 2/Phase 3Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Lanzhou for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

兰州大学第二医院

Lanzhou University Second Hospital

兰州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Second Hospital of Lanzhou University; Lanzhou University Second hospital; Xigu Branch of the Second Hospital of Lanzhou University; Lanzhou University Second Clinical Medical College

Suggest a correctionDownload the data